Thor Explorations remains Canaccord Genuity (TSX:CF, LSE:CF)’s top London gold producer pick after posting its first quarter 2023 operational update, with the miner reporting the production of 20,629 ounces of gold at its Segilola mine in Nigeria.
In a note to clients, Canaccord analysts reiterated their ‘Buy’ rating for the stock and price target of 35p. Thor’s London-listed shares are currently trading at 19p.
Century Lithium Corp announced that has received equipment from Koch Technology Solutions (KTS) related to the latter’s Li-Pro process for direct lithium extraction (DLE).
The KTS equipment has been installed and is now operating at Century Lithium's lithium extraction facility in Amargosa Valley, Nevada.
Peel Hunt reiterated its 'buy' recommendation and a 524p per share price target for Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) following the latest update from its phase I/II trial of the lead asset, a cancer drug called bexmarilimab.
The broker noted that one of the highlights of Monday's announcement was the drug's apparent ability to ignite an immune response in a patient who wasn't previously responding to the standard of care treatment, azacytidine.
BioVie announced that data abstracts from its Phase 2 trials evaluating NE3107 in degenerative dementias and Parkinson’s disease will be presented at the 2023 American Academy of Neurology Annual Meeting, being held virtually and in Boston, Massachusetts from April 22 to 27.
The company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB which lead to neuroinflammation and insulin resistance in neurodegenerative disease without impacting their homeostatic functions such as insulin signalling and neuron growth and survival, according to BioVie.
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application for its lead chronic kidney disease (CKD) program drug NP-251 (Repirinast).
The company said it has also filed corresponding patent applications in Canada, Europe, China and Japan. The US patent, number 17/258,402, is entitled ‘Compositions and Methods for Treating Non-Alcoholic Steatohepatitis’.
Anglo Asian Mining PLC (AIM:AAZ, OTC:AGXKF) said it produced 10,969 gold equivalent ounces from its operations in Azerbaijan during the three months to 31 March 2023.
Copper production increased by 49% year-on-year to 847 tonnes.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) produced 20,629 ounces of gold from its Segilola mine in Nigeria during the three months to end of March.
The average grade of the gold produced was 2.95 grammes per tonne.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has provided investors with encouraging additional phase I/II data on its cancer drug candidate, bexmarilimab.
The treatment is being tested in combination with standard treatments for patients with relapsed or unresponsive acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy specialist, has flagged a potential new use of its technology at the American Association for Cancer Research (AACR) annual meeting in Orlando, Florida, via a poster presentation.
The study demonstrated the potential of combining two different tests, immunofluorescent (IF) staining and HER2 fluorescence in-situ hybridisation (FISH) analysis, with cancer cells collected from the blood using ANGLE's Parsortix system.
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has the green light from the Human Research Ethics Committee (HREC) to start its Phase 1/2 intravenous (IV) clinical trial of its lead pipeline compound RECCE® 327 (R327) in healthy male and female subjects.
The trial will look at assessing R327 as an intravenous dose at faster infusion rates (15 minutes and 30 minutes) across roughly 12 participants in three cohorts.
Following the success of a pilot phase at its Kachi lithium project in Argentina, Lake Resources NL (ASX:LKE, OTCQB:LLKKF) is looking to a new phase of commercial-scale development.
In the latest development, Lake lauded the production of 2,500 kilograms of lithium carbonate equivalents (LCEs) at Kachi, extracted using an ion exchange method developed by technology partner Lilac Solutions that negates the need for evaporation ponds.
Majuba Hill Copper Corp has noted that on April 14, 2023, the British Columbia Securities Commission (BCSC) issued a finding under which it accepted an Agreed Statement of Facts dated May 27, 2022, wherein the company admitted liability for narrowed allegations made under its former president, CEO, and director Bryn Gardener-Evans. The BSCS executive director agreed that he would not seek any sanctions against the company in exchange for the Agreed Statement of Facts entered into with new management of the company. David Greenway, CEO of Majuba Hill commented: “I am pleased that matters appear to be proceeding in accordance with our agreement with counsel for the Executive Director. I want to assure shareholders and the many stakeholders that the former president, CEO, and director Mr Bryn Gardener-Evans has not been involved with the Company for over four years, and his long past actions do not reflect on the current board of directors and management of the Company. The management of the Company remains committed to increasing shareholder value with further development on our flagship Majuba Hill Copper project and look forward to 2023 exploration season."
Numinus Wellness Inc has announced that Payton Nyquvest, the company’s founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023, at 11.30am ET / 8.30am. PT. The discussion will focus on key takeaways from Numinus' fiscal Q2 2023 results, developments in the sector, and upcoming catalysts. Investors and other persons interested in participating, should register via the following link: https://us06web.zoom.us/webinar/register/WN_QMwqny4xT6CSp7v3MZpqzQ#/registration
Adamas One Corp has announced that its CEO Jay Grdina will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, Nevada. His presentation will be on April 26, 2023, at 11.00am Pacific Time via the following webcast link: https://www.webcaster4.com/Webcast/Page/2963/47996. Grdina will also be available for one-on-one meetings at the conference venue. To request a meeting and to register for the conference, interested parties can use the following link: https://planetmicrocapshowcase.com/signup
Forward Water Technologies Corp (FWTC) said it has entered into a contract with Global One Media effective April 5, 2023, to manage its social media channels including brand promotion, social media strategy and planning, monthly content calendar creation and lead generation.
Nextech3D.ai, formally Nextech AR Solutions Corp, which plans to release its fiscal year 2022 and fourth quarter 2022 audited financial results after the markets close on Thursday, April 20, 2023, has confirmed details for a conference call on Thursday, April 20, 2023, at 5.00pm Eastern Time. Evan Gappelberg, the company's chief executive officer, and Andrew Chan, its chief financial officer, will discuss the financial and operating results followed by a question and answer period. Conference Call Details: Participant Toll-Free Dial-In Number +1 (888) 330-2024; Participant Toll Dial-In Number +1 (646) 960-0187; Earnings Call ID: 7778367; Webcast Attendee URL https://events.q4inc.com/attendee/612528713. For those unable to join the live event, a recording of the presentation will be posted on the company's IR website: https://www.nextechar.com/investors/overview
BioVaxys Technology Corp has hired Maxim Group as its financial advisor and investment banker to help it list on a US national stock exchange. BioVaxys will issue Maxim 2,902,236 shares. "We look forward to working with Maxim Group to enhance shareholder value and unlock potential transformative capital market opportunities,” James Passin, CEO of BioVaxys, told investors.